Development and validation of a machine learning model to predict early recurrence after surgery in NSCLC patients

开发和验证用于预测非小细胞肺癌患者术后早期复发的机器学习模型

阅读:1

Abstract

To develop and validate a machine learning (ML) model for predicting early recurrence (ER) within two years post-surgery in non-small cell lung cancer (NSCLC) patients. This multicenter cohort study included 3,171 NSCLC patients who underwent radical surgery between January 2015 and January 2021. Patients were randomly allocated to training and testing cohorts, with nine machine learning algorithms employed to construct prediction models for early recurrence, and a stacking method utilized to combine the three best-performing models. Furthermore, external validation was performed from a single institution (n = 619). Model performance was evaluated using various metrics, including Area Under the Receiver Operating Characteristic Curve (AUC). SHapley Additive exPlanations (SHAP) methodology was used to interpret predictions. Among the cohort, 553 patients (17.4%) experienced ER, with common recurrence sites including the lung (35.2%), brain (24.1%), and bone (18.5%). Significant predictors identified included pathological T stage (pT3-4: 77% vs. 50%, p < 0.001), pathological N stage (pN1-2: 51% vs. 31%, p < 0.001), and tumor differentiation grade (poorly differentiated: 68% vs. 54%, p < 0.001). The stacking model achieved superior predictive performance (AUC = 0.81, accuracy = 0.83, Brier score = 0.03), outperforming individual ML models, whose AUC values ranged from 0.72 to 0.79. SHAP analysis revealed pT stage, maximum tumor diameter, and tumor markers as key determinants of ER risk. An online computing platform (https://nsclc-risk.shinyapps.io/NSCLC_early_recurrence/) for this stacking model is publicly available and free-to-use by doctors and patients. This study developed an interpretable ML model with high predictive performance for ER in post-operative NSCLC patients. The model, based on readily available clinical data, offers a valuable tool for personalized treatment decisions and follow-up strategies. Future prospective studies across multiple centers are needed to further validate the model's generalizability and accuracy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。